VEGFA - Vascular Endothelial Growth Factor A, also known as or Vascular permeability factor (VPF), is a major signaling growth factor member of the VEGF family, sub-group of the Platelet-Derived Growth Factor (PDFG) proteins, which is characterized by its conserved cystine-knot structure.1 VEGF expression is up regulated in hypoxia and in many types of cancers. Furthermore, VEGF receptors (VEGFR1 and VEGFR2) are also overexpressed in several tumors and studies have shown that high levels of VEGF correlates with poor prognosis.1-8 Inhibition of VEGF mediated angiogenesis signaling pathways have potential in angiogenesis-related disease therapy, this can be achieved by blocking either the circulating VEGF using Anti-VEGF antibodies such as Bevacizumab and Aflibercept5 or by VEGFR-2 inhibition using small molecules such as Gamabufotalin (CS-6) and Arenobufagin.6-8
Specificity
Monoclonal Anti-VEGF165 specifically recognizes human VEGFA isoform VEGF165 and does not recognize VEGF121 isoform.
Immunogen
Recombinant VEGF165 protein
Application
The antibody is recommended to use in various immunological techniques, including Immunoblot (~21 kDa). Detection of the VEGF165 band by Immunoblotting is specifically inhibited by the immunogen.
Biochem/physiol Actions
VEGF proteins are involved in angiogenesis and vasculogenesis, they predominantly activate proliferation and survival of endothelial cells and migration in non-endothelial cells.1VEGFA have several isoforms due to alternative splicing mainly at exons 6-8. The VEGF exon 8 splicing isoforms are divided into two groups, the “pro-angiogenic” VEGFxxxa isoforms considered to be activators of proliferation, survival and angiogenesis and the VEGFxxxb isoforms that are considered as “anti-angiogenic”.2
Physical form
Supplied as a solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide as a preservative.
Storage and Stability
For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Echinomycin (EKN), an inhibitor of hypoxia-inducible factor (HIF)-1 DNA-binding activity, has been implied as a possible therapeutic agent in ischemic diseases. Here, we assess EKN in hypoxia-driven responses in vitro using human primary adult retinal pigment epithelium cells (aRPE) and
Alternative splicing of vascular endothelial growth factor A (VEGFA) generates numerous isoforms with unique roles in tumor angiogenesis, and investigating the underlying mechanism during hypoxia necessitates diligent pursuance. Our research systematically demonstrated that the splicing factor SRSF2 causes the inclusion
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.